Health Technology Assessment

Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2018 conference in Barcelona, 10-14 November.

OHE presented at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare, held October 2018.

A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores potential solutions to these challenges. Three key topics are explored: uncertainty, discounting, and health outcomes and value. A series of recommendations are proposed.

OHE will be hosting two lunchtime seminars in October – one on the 22nd with Steven Pearson, ICER, and another on the 31st with Janel Hanmer, University of Pittsburgh.

Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.

When should progression-free survival be used as a surrogate for overall survival in oncology? Uneven reporting of results – different definitions and methods of analysis, lack of rigour in applying methodology – make progress difficult.

OHE’s Koonal Shah and Nancy Devlin are co-authors on two new papers focusing on the valuation of the EQ-5D-5L in Ireland.

This blog post discusses the role of social value judgements in NICE technology appraisals, focusing on the recent appraisal of dinutuximab beta for high-risk neuroblastoma.

A new OHE Research Paper sets out an agenda for the development of methods to estimate cost-effectiveness thresholds in the NHS.

Meet some of the OHE team at the Health Technology Assessment International (HTAi) 2018 conference in Vancouver, 1-5 June.

Pages

Subscribe to RSS - Health Technology Assessment